QUOTE AND NEWS
MedPage Today  Mar 22  Comment 
(MedPage Today) -- The drug has improved survival for the majority of CML patients
GenEng News  Mar 22  Comment 
Novartis' acute heart failure (AHF) drug serelaxin (RLX030), which both the FDA and the European regulatorĀ knocked back in 2014, failed in a global, 6600-patient Phase III study. The 3.5-year RELAX-AHF-2 trial evaluating serelaxin in addition to...
newratings.com  Mar 22  Comment 
NOVARTIS FINANCE S.A. / Novartis provides update on Phase III study of RLX030 (serelaxin) in patients with acute heart failure . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this...
FiercePharma  Mar 21  Comment 
Novartis star Cosentyx, facing new rivals, may gain edge as a disease-modifying med chelfand Tue, 03/21/2017 - 08:08
newratings.com  Mar 21  Comment 
BASEL (dpa-AFX) - Novartis (NVS) reported new data suggesting that Cosentyx may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance. The company said this is the first long-term data on psoriasis...
FiercePharma  Mar 18  Comment 
Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis tracy Sat, 03/18/2017 - 12:59
newratings.com  Mar 18  Comment 
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes Novartis International AG / New analysis shows Novartis Entresto improves glycemic control in reduced ejection...
Motley Fool  Mar 15  Comment 
Novartis' new cancer drug Kisqali stands ready to challenge Pfizer's Ibrance. But how serious is the threat?
Forbes  Mar 15  Comment 
Mike was told in the fall of 2010 that Pfizer was closing the Allergy & Respiratory diseases programs and his own role as the CSO of this group was being eliminated. Rather than seek employment elsewhere, Mike had others ideas.




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki